September 18th, 2013
Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.
November 28th, 2011
Three experts weigh in on findings from the ATLAS ACS 2-TIMI 51 and ADOPT trials.
August 28th, 2011
Several important questions about the relative safety and efficacy of apixaban versus warfarin in patients with nonvalvular atrial fibrillation have been answered.
August 24th, 2011
At 11:54 a.m. on August 28 in Paris (5:54 a.m. U.S. east coast time), I can almost imagine a huge drop in cell phone call volume as the ARISTOTLE presentation begins at ESC. The ESC exposition site is right next to Charles de Gaulle airport. Will a temporary “no fly zone” be declared? We know […]
March 18th, 2011
In a series of blog posts on CardioExchange, Samuel Goldhaber, Director of the Venous Thromboembolism Research Group in the Cardiovascular Division at Brigham and Women’s Hospital, has been guiding us on best practices around dabigatran. Recently, he teamed up with Elaine Hylek, Director of the Thrombosis and Anticoagulation Service at Boston University School of Medicine, […]
February 15th, 2011
CardioExchange welcomes Samuel Zachary Goldhaber, MD, Director of the Venous Thromboembolism Research Group and Medical Co-Director of the Anticoagulation Management Service at Brigham and Women’s Hospital in Boston. He answers practical questions from the CardioExchange editors about newly updated recommendations on the use of dabigatran in patients with atrial fibrillation, issued by the American College […]
December 7th, 2009
CardioExchange Editors: Given the results of both your RE-COVER study and the recently published RE-LY study, should anybody still be using warfarin? Goldhaber: Warfarin is not going to fade away into oblivion. Anyone currently stable on warfarin has little reason to abandon this time-tested drug. If once monthly INRs are usually in the therapeutic range, and if […]